Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 19, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $80.88 to $19,640,406.96.

Highlighted Stocks Traded by Insiders:

SCANA (SCG) - FREE Research Report

Sloan Maceo K, who is Director at SCANA, sold 2,620 shares at $51.68 on May 19, 2014. Following this transaction, the Director owned 57 shares meaning that the stake was reduced by 97.88% with the 2,620-share transaction.

The shares most recently traded at $50.71, down $0.97, or 1.9% since the insider transaction. Historical insider transactions for SCANA go as follows:

  • 4-Week # shares sold: 600
  • 12-Week # shares sold: 600
  • 24-Week # shares sold: 600

The average volume for SCANA has been 811,700 shares per day over the past 30 days. SCANA has a market cap of $7.3 billion and is part of the utilities sector and utilities industry. Shares are up 8.37% year-to-date as of the close of trading on Monday.

SCANA Corporation, through its subsidiaries, is engaged in the generation, transmission, distribution, and sale of electricity to retail and wholesale customers in South Carolina. It owns nuclear, coal, hydro, natural gas and oil, and biomass generating facilities. The stock currently has a dividend yield of 4.08%. The company has a P/E ratio of 14.2. Currently, there are 3 analysts who rate SCANA a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCG - FREE

TheStreet Quant Ratings rates SCANA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full SCANA Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Primerica (PRI) - FREE Research Report

Williams Glenn J., who is President at Primerica, sold 2,000 shares at $43.45 on May 19, 2014. Following this transaction, the President owned 79,961 shares meaning that the stake was reduced by 2.44% with the 2,000-share transaction.

The shares most recently traded at $43.53, up $0.08, or 0.18% since the insider transaction. Historical insider transactions for Primerica go as follows:

  • 4-Week # shares sold: 60,000
  • 12-Week # shares sold: 92,241
  • 24-Week # shares sold: 164,628

The average volume for Primerica has been 251,300 shares per day over the past 30 days. Primerica has a market cap of $2.4 billion and is part of the financial sector and insurance industry. Shares are up 2.77% year-to-date as of the close of trading on Monday.

Primerica, Inc., together with its subsidiaries, distributes financial products to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. The stock currently has a dividend yield of 1.11%. The company has a P/E ratio of 14.6. Currently, there is 1 analyst who rates Primerica a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRI - FREE

TheStreet Quant Ratings rates Primerica as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Primerica Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hospira (HSP) - FREE Research Report

Curran Connie R, who is Director at Hospira, sold 2,000 shares at $47.44 on May 19, 2014. Following this transaction, the Director owned 46,390 shares meaning that the stake was reduced by 4.13% with the 2,000-share transaction.

The shares most recently traded at $47.68, up $0.24, or 0.49% since the insider transaction. Historical insider transactions for Hospira go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Hospira has been 1.3 million shares per day over the past 30 days. Hospira has a market cap of $8.0 billion and is part of the health care sector and drugs industry. Shares are up 16.45% year-to-date as of the close of trading on Monday.

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. The company has a P/E ratio of 59.4. Currently, there are no analysts who rate Hospira a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HSP - FREE

TheStreet Quant Ratings rates Hospira as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Hospira Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null